Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
Prep Biochem Biotechnol ; 54(2): 218-225, 2024 Feb.
Article in English | MEDLINE | ID: mdl-37222635

ABSTRACT

Activin A, a member of the TGF-ß superfamily, is a homodimer of the inhibin ßΑ subunit that plays a diversity of roles in biological processes. Because of its multiple functions, significant efforts have been made to produce activin A, however, unsatisfactory results were obtained due to its low level of expression. In this study, a stable CHO cell line exhibiting high expression of rhActivin A was isolated and production of rhActivin A was achieved using the cell line from 11-day fed-batch cultures in a 7.5 L bioreactor. The production rate was 0.22 g/L, substantially higher than those reported in previous studies. The culture supernatant of the bioreactor was used to purify rhActivin A (purity: >99%, recovery rate: 47%). The purified rhActivin A exhibited biological activity, with an EC50 of 3.893 ng/mL and a specific activity of 1.38 × 103 IU/mg. The control of process-related impurities in the purified rhActivin A was successful and met the USP recommendations for use in cell therapy. Thus, our production and purification methods were appropriate for large-scale GMP-grade rhActivin A production, which can be used for various purposes including cell therapy.


Subject(s)
Activins , Bioreactors , Cricetinae , Animals , Humans , Cricetulus , CHO Cells , Recombinant Proteins/genetics
2.
Cell Death Differ ; 30(6): 1563-1574, 2023 06.
Article in English | MEDLINE | ID: mdl-37081114

ABSTRACT

At the top of the midbrain is the inferior colliculus (IC), which functions as the major hub for processing auditory information. Despite the functional significance of neurons in the IC, our understanding of their formation is limited. In this study, we identify the embryonic patterning gene Dbx1 as a key molecular player that governs genetic programs for IC survival. We find that Dbx1 plays a critical role in preventing apoptotic cell death in postnatal IC by transcriptionally repressing c-Jun and pro-apoptotic BH3 only factors. Furthermore, by employing combined approaches, we uncover that Tcf7l2 functions downstream of Dbx1. Loss of Tcf7l2 function causes IC phenotypes with striking similarity to those of Dbx1 mutant mice, which include defective embryonic maturation and postnatal deletion of the IC. Finally, we demonstrate that the Dbx1-Tcf7l2 cascade functions upstream of Ap-2δ, which is essential for IC development and survival. Together, these results unravel a novel molecular mechanism for IC maintenance, which is indispensable for normal brain development.


Subject(s)
Inferior Colliculi , Mesencephalon , Animals , Mice , Homeodomain Proteins/metabolism , Inferior Colliculi/metabolism , Mesencephalon/metabolism , Neurons/metabolism , Transcription Factor 7-Like 2 Protein/metabolism , Transcription Factor AP-2/genetics , Transcription Factor AP-2/metabolism
3.
Mol Cells ; 43(12): 975-988, 2020 Dec 31.
Article in English | MEDLINE | ID: mdl-33273139

ABSTRACT

Hypoxia plays important roles in cancer progression by inducing angiogenesis, metastasis, and drug resistance. However, the effects of hypoxia on long noncoding RNA (lncRNA) expression have not been clarified. Herein, we evaluated alterations in lncRNA expression in lung cancer cells under hypoxic conditions using lncRNA microarray analyses. Among 40,173 lncRNAs, 211 and 113 lncRNAs were up- and downregulated, respectively, in both A549 and NCI-H460 cells. Uroplakin 1A (UPK1A) and UPK1A-antisense RNA 1 (AS1), which showed the highest upregulation under hypoxic conditions, were selected to investigate the effects of UPK1AAS1 on the expression of UPK1A and the mechanisms of hypoxia-inducible expression. Following transfection of cells with small interfering RNA (siRNA) targeting hypoxiainducible factor 1α (HIF-1α), the hypoxia-induced expression of UPK1A and UPK1A-AS1 was significantly reduced, indicating that HIF-1α played important roles in the hypoxiainduced expression of these targets. After transfection of cells with UPK1A siRNA, UPK1A and UPK1A-AS1 levels were reduced. Moreover, transfection of cells with UPK1A-AS1 siRNA downregulated both UPK1A-AS1 and UPK1A. RNase protection assays demonstrated that UPK1A and UPK1A-AS1 formed a duplex; thus, transfection with UPK1A-AS1 siRNA decreased the RNA stability of UPK1A. Overall, these results indicated that UPK1A and UPK1A-AS1 expression increased under hypoxic conditions in a HIF-1α-dependent manner and that formation of a UPK1A/UPK1A-AS1 duplex affected RNA stability, enabling each molecule to regulate the expression of the other.


Subject(s)
Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Lung Neoplasms/genetics , RNA, Antisense/metabolism , RNA, Long Noncoding/genetics , Up-Regulation/genetics , Uroplakin Ia/genetics , Cell Hypoxia/genetics , Cell Line, Tumor , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Methylation , RNA Stability/genetics , RNA, Antisense/genetics , RNA, Long Noncoding/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/metabolism , Reproducibility of Results , Ribonucleases/metabolism
4.
Protein Expr Purif ; 176: 105744, 2020 12.
Article in English | MEDLINE | ID: mdl-32890706

ABSTRACT

The rhLIF is widely used as an essential factor in stem cell cultures for cell therapies. However, all the recombinant LIFs commercially available are expensive, and no commercially available rhLIF meet the standards recommended by USP for use in cell therapies. The current study reports the efficient production of N-glycosylated and bioactive rhLIF in CHO cells. The production rate of established rhLIF-expressing rCHO cells was approximately 0.85 g/l in 12-day fed-batch cultures using a 7.5 l bioreactor. The rhLIF protein was purified via a four-step purification procedure with approximately 57% recovery rate and greater than 99% purity. The purified rhLIF was N-glycosylated and biologically active with an EC50 of 0.167 ng/ml and a specific activity of 0.86 × 103 IU/mg. The purification procedure controlled the levels of process-related impurities below critical levels recommended by USP for cytokines used in cell therapies. The current work is the first production process of N-glycosylated and bioactive rhLIF, which can be applied to large-scale manufacture of GMP-grade rhLIF for use as an ancillary material in cell therapy.


Subject(s)
Leukemia Inhibitory Factor , Animals , CHO Cells , Cricetulus , Glycosylation , Humans , Leukemia Inhibitory Factor/biosynthesis , Leukemia Inhibitory Factor/chemistry , Leukemia Inhibitory Factor/genetics , Leukemia Inhibitory Factor/isolation & purification , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/isolation & purification
5.
Dev Dyn ; 249(5): 646-655, 2020 05.
Article in English | MEDLINE | ID: mdl-31872525

ABSTRACT

BACKGROUND: Dysfunction of GABAergic and glutamatergic neurons in the brain, which establish inhibitory and excitatory networks, respectively, may cause diverse neurological disorders. The mechanism underlying the determination of GABAergic vs. glutamatergic neurotransmitter phenotype in the caudal diencephalon remains largely unknown. RESULTS: In this study, we investigated the consequence of Tcf7l2 (transcription factor 7-like 2) ablation on the neurotransmitter identity of GABAergic and glutamatergic neurons in the caudal diencephalon. We identified positive and negative activity in the control of glutamatergic and GABAergic neuronal gene expression by Tcf7l2. Loss of Tcf7l2 did not alter the initial acquisition of the neurotransmitter identity in thalamic neurons. However, glutamatergic thalamic neurons failed to maintain their excitatory neurotransmitter phenotype in the absence of Tcf7l2. Moreover, a subset of Tcf7l2-deficient thalamic neurons underwent a glutamatergic to GABAergic neurotransmitter identity switch. Our data indicate that Tcf7l2 may promote glutamatergic neuronal differentiation and repress GABAergic neurotransmitter identity in the caudal thalamus. CONCLUSIONS: This study provides evidence for a novel and crucial role of Tcf7l2 in the molecular mechanism by which the neurotransmitter identity of glutamatergic thalamic neurons is established. Our findings exemplify a clear case of neurotransmitter identity regulation that is partitioned into initiation and maintenance phases.


Subject(s)
Thalamus , Transcription Factor 7-Like 2 Protein , Diencephalon , Neurons/metabolism , Neurotransmitter Agents/metabolism , Transcription Factor 7-Like 2 Protein/genetics , Transcription Factor 7-Like 2 Protein/metabolism
6.
Cell Mol Biol Lett ; 24: 28, 2019.
Article in English | MEDLINE | ID: mdl-31061665

ABSTRACT

BACKGROUND: Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor with a pivotal role in physiological and pathological responses to hypoxia. While HIF-1α is known to be involved in hypoxia-induced upregulation of microRNA (miRNA) expression, HIF-1α is also targeted by miRNAs. In this study, miRNAs targeting HIF-1α were identified and their effects on its expression and downstream target genes under hypoxic conditions were investigated. Cell migration under the same conditions was also assessed. METHODS: microRNAs that target HIF-1α were screened using 3'-untranslated region luciferase (3'-UTR-luciferase) reporter assays. The expression levels of HIF-1α and its downstream target genes after transfection with miRNA were assessed using quantitative RT-PCR and western blot analyses. The effect of the miRNAs on the transcriptional activity of HIF-1α was determined using hypoxia-responsive element luciferase (HRE-luciferase) assays. Cell migration under hypoxia was examined using the wound-healing assay. RESULTS: Several of the 19 screened miRNAs considerably decreased the luciferase activity. Transfection with miR-200c had substantial impact on the expression level and transcription activity of HIF-1α. The mRNA level of HIF-1α downstream genes decreased in response to miR-200c overexpression. MiR-200c inhibited cell migration in normoxia and, to a greater extent, in hypoxia. These effects were partly reversed by HIF-1α expression under hypoxic conditions. CONCLUSION: miR-200c negatively affects hypoxia-induced responses by downregulating HIF-1α, a key regulator of hypoxia. Therefore, overexpression of miR-200c might have therapeutic potential as an anticancer agent that inhibits tumor hypoxia.


Subject(s)
Cell Movement/genetics , Down-Regulation/genetics , Hypoxia-Inducible Factor 1, alpha Subunit/genetics , Lung Neoplasms/genetics , Lung Neoplasms/pathology , MicroRNAs/metabolism , 3' Untranslated Regions/genetics , Base Sequence , Cell Hypoxia/genetics , Cell Line, Tumor , DNA Methylation/genetics , Gene Expression Regulation, Neoplastic , Genes, Reporter , Humans , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Luciferases/metabolism , MicroRNAs/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Transcription, Genetic , Up-Regulation/genetics , Wound Healing
7.
J Microbiol Biotechnol ; 29(1): 55-58, 2019 Jan 28.
Article in English | MEDLINE | ID: mdl-30394043

ABSTRACT

Development of stable rCHO cell lines is still time consuming and labor intensive, although it is a critical step in the commercial development of recombinant antibodies. The current work demonstrates, for the first time, that electroporation of CHO cells with DMSO can enhance stable expression of recombinant antibodies in rCHO cells. Electroporation with DMSO resulted in an average 3.7-fold and 2.8-fold increases in expression levels of aflibercept and pembrolizumab, respectively, in pools of stable rCHO cells. It also resulted in an average of 2.2-fold and 2.6-fold increases in the expression of aflibercept and pembrolizumab, respectively, in single-cell derived rCHO clones. Simple batch cultures of rCHO cell clones with the highest expression produced 1.0 g/l for aflibercept and 1.4 g/l for pembrolizumab without a time-consuming gene amplification process. Electroporation with DMSO also shortened the development of rCHO cell lines to 2-3 months, allowing rapid establishment of stable rCHO cell lines with a desirable expression level antibodies.


Subject(s)
Antibodies/metabolism , Batch Cell Culture Techniques/methods , Dimethyl Sulfoxide , Electroporation , Animals , Antibodies/genetics , CHO Cells , Cell Culture Techniques , Cricetulus , Gene Expression , Gene Transfer Techniques , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism
8.
Dev Dyn ; 246(10): 749-758, 2017 10.
Article in English | MEDLINE | ID: mdl-28685891

ABSTRACT

BACKGROUND: The neurons contributing to thalamic nuclei are derived from at least two distinct progenitor domains: the caudal (cTH) and rostral (rTH) populations of thalamic progenitors. These neural compartments exhibit unique neurogenic patterns, and the molecular mechanisms underlying the acquisition of neurotransmitter identity remain largely unclear. RESULTS: T-cell acute lymphocytic leukemia protein 1 (Tal1) was expressed in the early postmitotic cells in the rTH domain, and its expression was maintained in mature thalamic neurons in the ventrolateral geniculate nucleus (vLG) and the intergeniculate leaflet (IGL). To investigate a role of Tal1 in thalamic development, we used a newly generated mouse line driving Cre-mediated recombination in the rTH domain. Conditional deletion of Tal1 did not alter regional patterning in the developing diencephalon. However, in the absence of Tal1, rTH-derived thalamic neurons failed to maintain their postmitotic neuronal features, including neurotransmitter profile. Tal1-deficient thalamic neurons lost their GABAergic markers such as Gad1, Npy, and Penk in IGL/vLG. These defects may be associated at least in part with down-regulation of Nkx2.2, which is known as a critical regulator of rTH-derived GABAergic neurons. CONCLUSIONS: Our results demonstrate that Tal1 plays an essential role in regulating neurotransmitter phenotype in the developing thalamic nuclei. Developmental Dynamics 246:749-758, 2017. © 2017 Wiley Periodicals, Inc.


Subject(s)
Neurotransmitter Agents , T-Cell Acute Lymphocytic Leukemia Protein 1/physiology , Thalamic Nuclei/cytology , Animals , Homeobox Protein Nkx-2.2 , Mice , Stem Cells , Thalamic Nuclei/embryology , Thalamus/cytology , Thalamus/embryology
9.
J Microbiol Biotechnol ; 27(7): 1281-1287, 2017 Jul 28.
Article in English | MEDLINE | ID: mdl-28535613

ABSTRACT

Bone morphogenetic protein-4 (BMP-4) is considered to have therapeutic potential for various diseases, including cancers; however, the high expression of biologically active recombinant human BMP-4 (rhBMP-4) needed for its manufacture for therapeutic purposes has yet to be established. In the current study, we established a recombinant Chinese hamster ovary (rCHO) cell line overexpressing rhBMP-4 as well as a production process using 7.5-l bioreactor (5 L working volume). The expression of the mature rhBMP-4 was significantly enhanced by recombinant furin expression. The combination of a chemically defined medium and a nutrient supplement solution for high expression of rhBMP-4 was selected and used for bioreactor cultures. The 11-day fed-batch cultures of the established rhBMP-4-expressing rCHO cells in the 7.5-L bioreactor produced approximately 32 mg/l of rhBMP-4. The mature rhBMP-4 was purified to homogeneity from the culture supernatant using a two-step chromatographic procedure, resulting in a recovery rate of approximately 55% and a protein purity greater than 95%. The N-terminal amino acid sequences and N-linked glycosylation of the purified rhBMP-4 were confirmed by N-terminal sequencing and de-N-glycosylation analysis, respectively. The mature purified rhBMP-4 has been proved to be functionally active, with an effective dose concentration of EC50 of 2.93 ng/ml.


Subject(s)
Bone Morphogenetic Protein 4/genetics , Bone Morphogenetic Protein 4/isolation & purification , Animals , Batch Cell Culture Techniques , Bioreactors , Bone Morphogenetic Protein 4/metabolism , Bone Morphogenetic Protein 4/pharmacology , CHO Cells , Cricetinae , Cricetulus , Gene Expression , Humans , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology
10.
Dev Biol ; 424(1): 62-76, 2017 04 01.
Article in English | MEDLINE | ID: mdl-28219675

ABSTRACT

The thalamus acts as a central integrator for processing and relaying sensory and motor information to and from the cerebral cortex, and the habenula plays pivotal roles in emotive decision making by modulating dopaminergic and serotonergic circuits. These neural compartments are derived from a common developmental progenitor domain, called prosomere 2, in the caudal forebrain. Thalamic and habenular neurons exhibit distinct molecular profile, neurochemical identity, and axonal circuitry. However, the mechanisms of how their progenitors in prosomere 2 give rise to these two populations of neurons and contribute to the forebrain circuitry remains unclear. In this study, we discovered a previously unrecognized role for Tcf7l2, a transcription factor known as the canonical Wnt nuclear effector and diabetes risk-conferring gene, in establishing neuronal identity and circuits of the caudal forebrain. Using genetic and chemical axon tracers, we showed that efferent axons of the thalamus, known as the thalamocortical axons (TCAs), failed to elongate normally and strayed from their normal course to inappropriate locations in the absence of Tcf7l2. Further experiments with thalamic explants revealed that the pathfinding defects of Tcf7l2-deficient TCAs were associated at least in part with downregulation of guidance receptors Robo1 and Robo2 expression. Moreover, the fasciculus retroflexus, the main habenular output tract, was missing in embryos lacking Tcf7l2. These axonal defects may result from dysregulation of Nrp2 guidance receptor. Strikingly, loss of Tcf7l2 caused a post-mitotic identity switch between thalamic and habenular neurons. Despite normal acquisition of progenitor identity in prosomere 2, Tcf7l2-deficient thalamic neurons adopted a molecular profile of a neighboring forebrain derivative, the habenula. Conversely, habenular neurons failed to maintain their normal post-mitotic neuronal identity and acquired a subset of thalamic neuronal features in the absence of Tcf7l2. Our findings suggest a unique role for Tcf7l2 in generating distinct neuronal phenotypes from homogeneous progenitor population, and provide a better understanding of the mechanism underlying neuronal specification, differentiation, and connectivity of the developing caudal forebrain.


Subject(s)
Habenula/cytology , Habenula/embryology , Nerve Net/metabolism , Neurons/metabolism , Thalamus/cytology , Thalamus/embryology , Transcription Factor 7-Like 2 Protein/metabolism , Animals , Axon Guidance , Axons/metabolism , Biomarkers/metabolism , Body Patterning , Diencephalon/embryology , Diencephalon/metabolism , Homeodomain Proteins/metabolism , Mice , Mitosis , Mutation/genetics , Protein Binding , Stem Cells/metabolism , Transcription, Genetic
11.
Genesis ; 55(3)2017 03.
Article in English | MEDLINE | ID: mdl-28093895

ABSTRACT

The sine oculis homeobox protein Six3 plays pivotal roles in the development of the brain and craniofacial structures. In humans, SIX3 haploinsufficiency results in holoprosencephaly, a defect in anterior midline formation. Although much is known about the evolutionarily conserved functions of Six3, the regulatory mechanism responsible for the expression pattern of Six3 remains relatively unexplored. To understand how the transcription of Six3 is controlled during embryogenesis, we screened ∼300 kb of genomic DNA encompassing the Six3 locus for cis-acting regulatory elements capable of directing reporter gene expression to sites of Six3 transcription in transgenic mouse embryos. We identified a novel enhancer element, whose activity recapitulates endogenous Six3 expression in the ventral midbrain, pretectum, and thalamus. Cross-species comparisons revealed that this Six3 brain enhancer is functionally conserved in other vertebrates. We also showed that normal Six3 transcription in the ventral midbrain and pretectum is dependent on Ascl1, a basic helix-loop-helix proneural factor. Moreover, loss of Ascl1 resulted in downregulation of the Six3 brain enhancer activity, emphasizing its unique role in regulating Six3 expression in the developing brain.


Subject(s)
Brain/metabolism , Conserved Sequence , Enhancer Elements, Genetic , Eye Proteins/genetics , Homeodomain Proteins/genetics , Nerve Tissue Proteins/genetics , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Basic Helix-Loop-Helix Transcription Factors/metabolism , Brain/embryology , Eye Proteins/metabolism , Gene Expression Regulation, Developmental , Homeodomain Proteins/metabolism , Mice , Nerve Tissue Proteins/metabolism , Homeobox Protein SIX3
12.
Protein Expr Purif ; 120: 87-91, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26711959

ABSTRACT

Bone morphogenetic protein-7 is a multifunctional growth factor involved in various cellular processes such as osteogenesis, kidney and eye development, brown adipogenesis, and bone metastasis, and thus has been considered to have therapeutic potential for treating various diseases. In this study, we established a Chinese hamster ovary (CHO) cell line stably overexpressing recombinant human BMP-7 (rhBMP-7). Over the course of a 14-day fed-batch culture process in a 7.5-l bioreactor (5-l working volume) using chemically defined medium, the established cells could produce over 188 mg/l of rhBMP-7 protein. The rhBMP-7 was purified to homogeneity from the culture supernatant using a two-step chromatographic procedure that resulted in a recovery rate of approximately 55%, with protein purity greater than 95%. The purified rhBMP-7 was further demonstrated to be functionally active by measuring the proliferation of MC3T3-E1 cells, revealing a half-maximal effective concentration of 28.31 ng/ml.


Subject(s)
Bone Morphogenetic Protein 7 , Animals , Bioreactors , CHO Cells , Chromatography , Cloning, Molecular , Cricetulus/genetics , Humans , Recombinant Proteins
13.
Exp Cell Res ; 339(2): 320-32, 2015 Dec 10.
Article in English | MEDLINE | ID: mdl-26485640

ABSTRACT

Micro(mi)RNAs play important and varied roles in tumorigenesis; however, the full repertoire of miRNAs that affect cancer cell growth is not known. In this study, an miRNA library was screened to identify those that affect the growth of A549 tumor cells. Among 300 miRNAs, miR-28-5p, -323-5p, -510-5p, -552-3p, and -608 were the most effective in inhibiting cell growth. More specifically, overexpressing miR-28-5p, -323-5p, and -510-5p induced G1 arrest, as determined by flow cytometry, whereas that of miR-608 induced cell death in a caspase-dependent manner. Moreover, several genes involved in apoptosis and cell cycle progression were downregulated upon overexpression of each of the five miRNAs, with the functional targets of miR-552-3p and miR-608 confirmed by microarray, quantitative real-time PCR, and luciferase reporter assay. In miR-608-transfected cells, B cell lymphoma 2-like 1 (BCL2L1), D-type cyclin 1 (CCND1), CCND3, cytochrome b5 reductase 3 (CYB5R3), phosphoinositide 3-kinase regulatory subunit 2 (PIK3R2), specificity protein 1 (SP1), and phosphorylated Akt were all downregulated, while Bcl-2-interacting killer (BIK) was upregulated. Moreover, miR-608 was determined to have a suppressive function on tumor growth in an NCI-H460 xenograft model. These findings provide insights into the roles of five miRNAs in growth inhibition and their potential function as cancer therapeutics.


Subject(s)
Apoptosis/genetics , Cell Cycle/genetics , Gene Library , MicroRNAs/analysis , MicroRNAs/genetics , Animals , Cell Line, Tumor , Cell Proliferation/genetics , Female , Humans , Mice , Mice, Inbred BALB C , Mice, Nude , MicroRNAs/metabolism , Neoplasms, Experimental/genetics , Neoplasms, Experimental/pathology , Xenograft Model Antitumor Assays
14.
Clin Drug Investig ; 35(10): 659-64, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26369656

ABSTRACT

BACKGROUND AND OBJECTIVES: A new biosimilar human recombinant epoetin alfa product (PDA10) has been developed by PanGen Biotech Inc., Korea. This study was planned to demonstrate the pharmacokinetic and pharmacodynamic comparability of PDA10 to an existing epoetin alfa (Eprex) after a single intravenous administration to healthy adult male volunteers. METHODS: A randomized, double-blinded, single-dose, crossover study was conducted in 30 subjects. The subjects were assigned randomly to one of two sequence groups, and single doses of 100 IU/kg PDA10 or Eprex were administered intravenously on each of 2 treatment days separated by a 4-week washout period. Plasma erythropoietin concentrations were measured using an enzyme-linked immunosorbent assay and the pharmacokinetic parameters of the two treatments were compared. The time course and area under the effect curve (AUEC) of absolute reticulocyte counts were used as surrogate parameters for the pharmacodynamic evaluation. Adverse events (AEs) were recorded. RESULTS: A total of 30 subjects were enrolled, and 27 completed the study. The geometric mean ratios (PDA10/Eprex) of erythropoietin for maximum plasma concentration (C max) and area under the plasma concentration-time curve to the last measurable concentration (AUC0-last) after intravenous administration of 100 IU/kg were 1.00 (90% confidence interval [CI] 0.96-1.05) and 0.96 (90% CI 0.93-1.00). The absolute reticulocyte counts of PDA10 and Eprex were similar, as determined from the maximum reticulocyte count and AUEC0-last values. Treatment-emergent AEs were mild and occurred in seven subjects. CONCLUSION: PDA10 and Eprex met the regulatory criteria for bioequivalence with respect to their pharmacokinetic profiles and pharmacodynamic actions.


Subject(s)
Biosimilar Pharmaceuticals/administration & dosage , Biosimilar Pharmaceuticals/pharmacokinetics , Epoetin Alfa/administration & dosage , Epoetin Alfa/pharmacology , Epoetin Alfa/pharmacokinetics , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacokinetics , Adult , Biosimilar Pharmaceuticals/adverse effects , Chemistry, Pharmaceutical , Cross-Over Studies , Double-Blind Method , Epoetin Alfa/adverse effects , Healthy Volunteers , Humans , Male , Recombinant Proteins/adverse effects , Republic of Korea , Reticulocyte Count , Therapeutic Equivalency , Young Adult
15.
Genesis ; 53(6): 356-65, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25950659

ABSTRACT

The mammalian diencephalon is the caudal derivative of the embryonic forebrain. Early events in diencephalic regionalization include its subdivision along the dorsoventral and anteroposterior axes. The prosomeric model by Puelles and Rubenstein (1993) suggests that the alar plate of the posterior diencephalon is partitioned into three different prosomeres (designated p1-p3), which develop into the pretectum, thalamus, and prethalamus, respectively. Here, we report the developmental consequences of genetic ablation of cell populations from the diencephalic basal plate. The strategy for conditionally regulated cell ablation is based on the targeted expression of the diphtheria toxin gene (DTA) to the diencephalic basal plate via tamoxifen- induced, Cre-mediated recombination of the ROSA(DTA) allele. We show that activation of DTA leads to specific cell loss in the basal plate of the posterior diencephalon, and disrupted early regionalization of distinct alar territories. In the basal plate-deficient embryos, the p1 alar plate exhibited reduced expression of subtype-specific markers in the pretectum, whereas p2 alar plate failed to further subdivide into two discrete thalamic subpopulations. We also show that these defects lead to abnormal nuclear organization at later developmental stages. Our data have implications for increased understanding of the interactive roles between discrete diencephalic compartments.


Subject(s)
Diencephalon/embryology , Diencephalon/metabolism , Diphtheria Toxin/genetics , Embryo, Mammalian/metabolism , Gene Expression Regulation, Developmental , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Basic Helix-Loop-Helix Transcription Factors/metabolism , Diencephalon/anatomy & histology , Diphtheria Toxin/metabolism , Embryo, Mammalian/cytology , Embryo, Mammalian/embryology , GATA3 Transcription Factor/genetics , GATA3 Transcription Factor/metabolism , Hedgehog Proteins/genetics , Hedgehog Proteins/metabolism , Immunohistochemistry , In Situ Hybridization , Mice, Transgenic , Organogenesis/genetics , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , T-Cell Acute Lymphocytic Leukemia Protein 1 , Time Factors
16.
Protein Expr Purif ; 110: 102-6, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25727048

ABSTRACT

Transforming growth factor beta 3 (TGFß3) is an important cytokine, functioning in cell proliferation and differentiation, and has been considered to have therapeutic potential for treating various diseases and for scar reduction in adult wound healing. In the current study, a Chinese hamster ovary (CHO) cell line overexpressing recombinant human TGFß3 (rhTGFß3) was established. Through a 15-day fed-batch culture process in a 7.5-l bioreactor (5-l working volume) using chemically defined medium, the established cells could produce over 133mg/l of rhTGFß3 protein. The rhTGFß3 was purified to homogeneity from the culture supernatant using a two-step chromatographic procedure, resulting in a recovery rate of approximately 65%, with protein purity greater than 97%. The N-terminal amino acid sequences of the purified rhTGFß3 were confirmed by N-terminal sequencing analysis. The purified rhTGFß3 was further demonstrated to be functionally active by measuring the inhibition of growth of HT-2 cells, revealing a half-maximal effective concentration of 42.11pg/ml and specific activity of 1.84×10(7)U/mg.


Subject(s)
Plasmids/chemistry , Recombinant Proteins/genetics , Transforming Growth Factor beta3/genetics , Amino Acid Sequence , Animals , Batch Cell Culture Techniques , Bioreactors , CHO Cells , Cell Proliferation/drug effects , Cloning, Molecular , Cricetulus , Culture Media/chemistry , Gene Expression , Humans , Mice , Molecular Sequence Data , Plasmids/metabolism , Protein Structure, Tertiary , Recombinant Proteins/chemistry , Recombinant Proteins/isolation & purification , Recombinant Proteins/pharmacology , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Transforming Growth Factor beta3/chemistry , Transforming Growth Factor beta3/isolation & purification , Transforming Growth Factor beta3/pharmacology
17.
Dev Biol ; 398(2): 280-91, 2015 Feb 15.
Article in English | MEDLINE | ID: mdl-25512300

ABSTRACT

The mammalian thalamus is an essential diencephalic derivative that plays unique roles in processing and relaying sensory and motor information to and from the cerebral cortex. The profile of transcription factors and lineage tracing experiments revealed a spatiotemporal relationship between diencephalic progenitor domains and discrete differentiated neurons contributing to thalamic nuclei. However, the precise molecular mechanisms by which heterogeneous thalamic neurons become specified and assemble into distinct thalamic nuclei are still poorly understood. Here, we show that a combinatorial interaction between the bHLH transcription factors Ascl1 and Helt is required for acquiring thalamic progenitor identity. Surprisingly, in the combined absence of Ascl1 and Helt, rostral thalamic progenitors (TH-R) adopt a molecular profile of a more rostral diencephalic derivative, the prethalamus. Furthermore, we show that the prethalamic factors Dlxs upregulated by Ascl1/Helt deficiency play unique roles in regulating thalamic progenitor specification, and that derepression of Dlx2 and Dlx5 suppress generation of TH-R neurons. Taken together, our results suggest a model whereby the combined activity of two distinct bHLH factors plays a key role in the development of discrete classes of thalamic interneurons.


Subject(s)
Basic Helix-Loop-Helix Transcription Factors/metabolism , Homeodomain Proteins/metabolism , Neurons/metabolism , Repressor Proteins/metabolism , Thalamus/cytology , Transcription Factors/metabolism , Animals , Binding Sites , Body Patterning/genetics , Cell Lineage , GATA2 Transcription Factor/metabolism , Gene Expression Regulation, Developmental , Homeodomain Proteins/genetics , Mice , Neural Stem Cells/cytology , Neural Stem Cells/metabolism , Neurons/cytology , Trans-Activators/metabolism , Transcription Factors/genetics
18.
Mol Cells ; 37(4): 314-21, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24802056

ABSTRACT

CDK2 is a key regulator of cell cycle progression. In this study, we screened for miRNAs targeting CDK2 using a luciferase-3'-untranslated region reporter assay. Among 11 hit miRNAs, miR-509-3p reduced CDK2 protein levels and significantly inhibited cancer cell growth. Microarray, Western blotting, and luciferase reporter analyses revealed additional targets of miR-509-3p, including Rac1 and PIK3C2A. Overexpression of miR-509-3p induced G1 cell-cycle arrest and inhibited colony formation and migration. RNAi experiments indicated that the growth-inhibitory effects of miR-509-3p may occur through down-regulation of CDK2, Rac1, and PIK3C2A. Targeting of multiple growth regulatory genes by miR-509-3p may contribute to effective anti-cancer therapy.


Subject(s)
Cyclin-Dependent Kinase 2/metabolism , MicroRNAs/metabolism , Neoplasms/therapy , Phosphatidylinositol 3-Kinases/metabolism , rac1 GTP-Binding Protein/metabolism , Cell Cycle/genetics , Cell Movement/genetics , Cell Proliferation/genetics , Cyclin-Dependent Kinase 2/genetics , Down-Regulation/genetics , HeLa Cells , Humans , MicroRNAs/genetics , Microarray Analysis , Neoplasms/genetics , Neoplastic Stem Cells , Phosphatidylinositol 3-Kinases/genetics , RNA, Small Interfering/genetics , Transgenes/genetics , rac1 GTP-Binding Protein/genetics
19.
Dev Biol ; 381(2): 491-501, 2013 Sep 15.
Article in English | MEDLINE | ID: mdl-23792023

ABSTRACT

The SRY-related HMG box transcription factor Sox2 plays critical roles throughout embryogenesis. Haploinsufficiency for SOX2 results in human developmental defects including anophthalmia, microphthalmia and septo-optic dysplasia, a congenital forebrain defect. To understand how Sox2 plays a role in neurogenesis, we combined genomic and in vivo transgenic approaches to characterize genomic regions occupied by Sox2 in the developing forebrain. Six3, a homeobox gene associated with holoprosencephaly, a forebrain midline defect, was identified as a Sox2 transcriptional target. This study shows that Sox2 directly regulates a previously unidentified long-range forebrain enhancer to activate Six3 expression in the rostral diencephalon. Further biochemical and genetic evidences indicated a direct regulatory link between Sox2 and Six3 during forebrain development, providing a better understanding of a common molecular mechanism underlying these forebrain defects.


Subject(s)
Eye Proteins/metabolism , Gene Expression Regulation, Developmental , Homeodomain Proteins/metabolism , Nerve Tissue Proteins/metabolism , Prosencephalon/metabolism , SOXB1 Transcription Factors/genetics , Animals , Base Sequence , Binding Sites , Conserved Sequence , Embryo, Mammalian/metabolism , Embryonic Development , Enhancer Elements, Genetic , Evolution, Molecular , Eye Proteins/genetics , Hedgehog Proteins/genetics , Hedgehog Proteins/metabolism , Homeodomain Proteins/genetics , Mice , Mice, Transgenic , Nerve Tissue Proteins/genetics , Neural Plate/embryology , Neural Plate/metabolism , Prosencephalon/cytology , Prosencephalon/embryology , Protein Binding , SOXB1 Transcription Factors/metabolism , Transcriptional Activation , Homeobox Protein SIX3
20.
Biotechnol Lett ; 35(7): 987-93, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23468139

ABSTRACT

The gradual loss of recombinant protein expression in CHO cell lines during prolonged subculture is a common issue, referred to as instability, which seriously affects the industrial production processes of therapeutic proteins. Loss of recombinant gene copies, due to the genetic instability of CHO cells, and epigenetic silencing of transgene sequences, are the main reported causes of production instability. To increase our understanding on the molecular mechanisms inherent to CHO cells involved in production instability, we explored the molecular features of stable and unstable antibody producing cell lines obtained without gene amplification, to exclude the genetic instability induced by the gene amplification process. The instability of recombinant antibody production during long-term culture was caused by a 48-53% decrease in recombinant mRNA levels without significant loss of recombinant gene copies, but accompanied by a ~45% decrease in histone H3 acetylation (H3ac). Thus, our results suggest a critical role of H3ac in the stability of recombinant protein production.


Subject(s)
Antibodies/metabolism , Epigenesis, Genetic , Gene Expression , Histones/metabolism , Acetylation , Animals , Antibodies/genetics , CHO Cells , Cell Culture Techniques/methods , Cricetulus , Genomic Instability , Protein Processing, Post-Translational , Recombinant Proteins/genetics , Recombinant Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...